Frontiers in Oncology (Oct 2019)

Clinical Outcome Assessments Toolbox for Radiopharmaceuticals

  • Charles A. Kunos,
  • Jacek Capala,
  • Adam P. Dicker,
  • Benjamin Movsas,
  • Susan Percy Ivy,
  • Lori M. Minasian

DOI
https://doi.org/10.3389/fonc.2019.01028
Journal volume & issue
Vol. 9

Abstract

Read online

For nearly 40 years, the U.S. National Cancer Institute (NCI) has funded health-related quality-of-life (HRQOL) and symptom management in oncology clinical trials as a method for including a cancer patient's experience during and after treatment. The NCI's planned scope for HRQOL, symptom and patient-reported outcomes management research is explained as it pertains to radiopharmaceutical clinical development. An effort already underway to support protocol authoring via an NCI Cancer Therapy Evaluation Program (CTEP) Centralized Protocol Writing Service (CPWS) is described as this service aids incorporation of HRQOL, symptom and patient-reported outcomes management research into sponsored protocols.

Keywords